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cells into GABAergic neurons prior to transplant
results in greater repopulation of the damaged
brain and accelerates functional recovery after
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Abstract
Introduction: Despite attempts to prevent brain injury during the hyperacute phase of stroke, most sufferers end
up with significant neuronal loss and functional deficits. The use of cell-based therapies to recover the injured brain
offers new hope. In the current study, we employed human neural stem cells (hNSCs) isolated from subventricular
zone (SVZ), and directed their differentiation into GABAergic neurons followed by transplantation to ischemic brain.
Methods: Pre-differentiated GABAergic neurons, undifferentiated SVZ-hNSCs or media alone were stereotaxically
transplanted into the rat brain (n=7/group) 7 days after endothelin-1 induced stroke. Neurological outcome was
assessed by neurological deficit scores and the cylinder test. Transplanted cell survival, cellular phenotype and
maturation were assessed using immunohistochemistry and confocal microscopy.
Results: Behavioral assessments revealed accelerated improvements in motor function 7 days post-transplant in
rats treated with pre-differentiated GABAergic cells in comparison to media alone and undifferentiated hNSC
treated groups. Histopathology 28 days-post transplant indicated that pre-differentiated cells maintained their
GABAergic neuronal phenotype, showed evidence of synaptogenesis and up-regulated expression of both GABA
and calcium signaling proteins associated with neurotransmission. Rats treated with pre-differentiated cells also
showed increased neurogenic activity within the SVZ at 28 days, suggesting an additional trophic role of these
GABAergic cells. In contrast, undifferentiated SVZ-hNSCs predominantly differentiated into GFAP-positive astrocytes
and appeared to be incorporated into the glial scar.
Conclusion: Our study is the first to show enhanced exogenous repopulation of a neuronal phenotype after stroke
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Introduction
Stroke is an acute cerebrovascular disorder that remains
a major cause of death and disability in the industrial-
ized world [1]. Aside from thrombolysis, which is limited
by a narrow therapeutic window, there is no effective
therapeutic treatment proven to promote neurological
recovery in the postischemic phase [2].
Regenerative events initiated following brain damage
are active for weeks following stroke [3, 4], which poten-
tially provides a second window for treatment. Although
there are promising treatment strategies that target brain
regeneration, including repetitive training, exercise, and
physical therapy [5–7], many stroke survivors are often
not able to participate in rehabilitation programs until
many weeks after a stroke event and delayed rehabilita-
tion results in worse outcomes [8].
Exogenous cell-based therapies to complement en-
dogenous repair mechanisms are currently being trialed in
humans following extensive meta-analysis of over 40 stud-
ies reporting significant improvements in function after
cell transplantation in ischemic animal models [9–11].
Despite early reports of functional benefits in humans [12,
13], a cellular basis for neurological improvement still re-
mains elusive [14]. Whilst neural cell replacement may be
achieved, new research shows that neural stem cells
(NSCs) can exert trophic effects through secretion of
protein factors which induce change in the host tissue
to promote functional improvements [15]. In addition
to identifying how these cells work, it is equally im-
portant to isolate factors that influence stem cell sur-
vival and long-term integration within host tissue.
To date, all preclinical and clinical stem cell transplant
studies for the treatment of stroke have been conducted
using undifferentiated stem cells [10, 16, 17]. Survival of
these cells ranges between 0.5 and 30 % [17–23], and al-
though they are capable of forming neuronal populations
after transplant in animal models, cells most predomin-
antly differentiate into astrocytes [16, 17, 20]. Functional
recovery in these studies has therefore been suggested to
be due to trophic support [19, 24], but this effect has
not been well characterized or documented.
Recent reports in other models of neurological disease
suggest that predifferentiating stem cells into a neuronal
phenotype prior to transplant might be a better ap-
proach [25–28]. Indeed, differentiated human neural
progenitor cell-derived GABAergic neurons injected into
the spinal cord following spinal cord injury result in
long-term survival of GABAergic cells that generate glu-
tamic acid decarboxylase, gamma-aminobutyric acid
(GABA), and β-III tubulin, resulting in functional im-
provement [26]. We therefore see value in using a simi-
lar approach for promoting recovery after stroke. To this
end, we have employed human neural stem cells
(hNSCs) isolated from the subventricular zone (SVZ)
[29] and directed their differentiation into GABAergic
neuronal cells. In the present study we investigated the
effect of transplanting undifferentiated SVZ-hNSCs ver-
sus predifferentiated SVZ-hNSCs into the rat brain 7
days after stroke. We determined the optimal phenotypic
conditions that translate into best outcomes in terms of
cell survival, histopathology, and functional recovery.
Materials and methods
The following experiments were conducted in adherence
with current RIGOR guidelines [30, 31] and included
randomization of treatments, blinding during assess-
ment, inclusion of appropriate control groups, and full
statistical analysis involving power calculations in consult-
ation with the Statistical Consulting Centre, University of
Melbourne, Victoria, Australia.
Ethics statement and animals
All experiments were performed in strict accordance
with the guidelines of the National Health & Medical
Research Council of Australia Code of Practice for the
Care and Use of Animals for Experimental Purposes in
Australia. The protocol was approved by the St Vincent’s
Hospital animal ethics committee (AEC009/09). Surgeries
were performed under general anesthesia and paracetamol
(2 mg/kg in drinking water) was provided 24 hours
prior to and after surgery to minimize distress. A
total of 30 adult male Hooded Wistar rats weighing
300–360 g (Laboratory Animal Services, University of
Adelaide, Australia) were used for experiments. Rats
were group housed (four rats/cage) prior to stroke,
whereupon they were individually housed on a 12-
hour light/dark cycle with ad libitum access to food
and water.
Surgical preparation
Rats were anesthetized with a mixture of ketamine/xyla-
zine (75 mg/kg:10 mg/kg respectively intraperitoneally)
and maintained throughout surgery by inhalation isoflur-
ane (95 % O2 and 5 % isoflurane). A 23-gauge stainless
steel guide cannula was stereotaxically implanted into
the cortex 2 mm dorsal to the right middle cerebral ar-
tery (MCA) (0.2 mm anterior, –5.9 mm lateral, –5.2 mm
ventral) as in previous studies [32, 33]. Rats were
allowed to recover for 5 days prior to stroke induction.
Endothelin-1-induced stroke
Focal cerebral ischemia was induced in conscious rats
(n = 30) by constriction of the right MCA with perivas-
cular administration of endothelin-1 (ET-1, 60 ρmol in 3
μl saline over 10 minutes; American Peptide Company,
Inc., CA, USA) [32, 33]. Characteristic behavioral
changes indicative of stroke were scored 1–5 for stroke
severity according to our previously established protocol,
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with 5 being the most severe [33]. Rats that did not dis-
play behavioral changes were considered not to have suf-
fered a stroke and were excluded from further study.
Only rats with an initial stroke severity score of 4, and
with clear deficits of ≥3 according to the neurological
deficit score at 7 days, were used for stem cell trans-
plants so as to minimize sample variation associated
with different stroke outcomes [32, 33].
In vitro cell preparation
hNSC expansion, medium preparation and handling
Experiments were conducted using hNSCs isolated from
the SVZ of human fetal brain tissues (14–21 weeks) that
were obtained following donor consent under the strict
guidelines approved by the Singapore National Health-
care Group Domain Specific Review Board (reference:
D/06/154) [29]. The hNSCs were cultured as free-floating
neurospheres using protocols described previously.
Prior to transplant, cryopreserved SVZ-hNSCs were
thawed, passaged 48 hours later, and expanded as de-
scribed previously [29]. Briefly, cells were collected and
mechanically dissociated by trituration, and approximately
0.7 × 106 cells/well were plated into low-adherence six-
well plates (Corning Costar, Sigma-Aldrich, St. Louis,
MO, USA). For expansion, cultures were maintained in
complete media (Neurocult NS-A hNSC proliferation
media and supplement; Stem Cell Technologies Inc., Tul-
lamarine, VIC, Australia), human epidermal growth factor
(EGF, 20 ng/ml; Peprotech, Rocky Hill, NJ, USA), human
basic fibroblast growth factor (bFGF, 20 ng/ml; Pepro-
tech), heparin (2 μg/ml; Sigma-Aldrich, St. Louis, MO,
USA), and 1 % penicillin/streptomycin (Gibco, Thermo
Fisher Scientific, Waltham, MA, USA) at 37 °C in a hu-
midified incubator (5 % CO2 atmosphere) for a minimum
of 14 days to reach appropriate numbers required for dif-
ferentiation and transplantation. A 50 % media change
was performed every second day. Cell density and viability
(≥90 %) was determined using the standard 0.1 % trypan
blue exclusion test [29].
In vitro differentiation of hNSCs
For differentiation of SVZ-hNSCs, neurospheres were
first dissociated into single-cell suspensions with TryplE,
and then cultured in differentiation media consisting of
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Invi-
trogen, Thermo Fisher Scientific) and neurobasal media
(1:1) supplemented with 1 % StemPro neural (Invitrogen),
0.5 % N2 (Gibco), and 50 ng/ml brain-derived neuro-
trophic factor (BDNF; Peprotech) to induce differenti-
ation as described previously [29]. All cultures were
maintained at 37 °C in a humidified culture incubator
(5 % CO2 atmosphere) for 7 days, with a 50 % differentiation
media change every second day.
In vitro immunocytochemistry
To determine the phenotype of undifferentiated (day 0)
cells, SVZ-hNSC neurospheres were seeded onto poly-L-
lysine-coated (Sigma-Aldrich, St. Louis, MO, USA) and
laminin-coated (Sigma) eight-well chamber slides (Nunc
Lab-Tek, Thermo Fisher Scientific) at a density of ap-
proximately 200,000 cells/ml. After seeding, for day 0
analysis, neurospheres were allowed to attach for 2
hours at 37 °C under 5 % CO2 before removal of media
and fixation with 4 % paraformaldehyde (PFA) in 0.1 M
phosphate-buffered saline (PBS) for 15 minutes for im-
munocytochemical analysis. For analysis of differentiated
SVZ-hNSCs (day 7), hNSCs were seeded onto poly-L-ly-
sine-coated (Sigma) and laminin-coated (Sigma) eight-
well chamber slides as already described. SVZ-hNSCs were
placed in differentiation media as described earlier and
after 7 days the cells were fixed with 4 % PFA for 10 mi-
nutes at room temperature, washed (1 × 5 minutes in
0.1 M PBS), and processed for immunocytochemistry.
Immunofluorescence was performed on in vitro cell cul-
ture chamber slides to analyze phenotypic profiles as de-
scribed previously [26]. Briefly, cells were blocked with
5 % normal goat serum (NGS) (or 1 % bovine serum albu-
min [BSA; Sigma-Aldrich, St. Louis, MO, USA] for all
staining with goat anti-parvalbumin (PV) antibody) in
0.1 % Triton X-100 in 0.1 M PBS for 20 minutes before
SVZ-hNSCs were identified using primary antibodies
including mouse anti-human specific nuclear antigen
(HuNu, 1:1000; Millipore, Billerica, MA, USA), rabbit
anti-neuronal class III β-tubulin (Tuj1, 1:1000; Cov-
ance Inc., Sydney, NSW, Australia), rabbit anti-GABA
(1:1000; Sigma), rabbit anti-Nestin (1:1000; Millipore),
rabbit anti-glial fibrillary acidic protein (GFAP, 1:1000;
DAKO, Glostrup, Hovedstaden, Denmark), guinea-pig
anti-doublecortin (DCX, 1:500; Millipore), rabbit anti-
neuronal nuclear antigen (NeuN, 1:1000; Millipore), rabbit
anti-Ki67 (1:500; Thermo Fisher Scientific), rabbit anti-
SOX2 (1:400; Millipore), rabbit anti-glutamate decarboxyl-
ase 65&67 (GAD, 1:1000; Millipore), rabbit anti-
synaptophysin (SYN, 1:200; Sigma), chicken Tuj1 (1:200;
Millipore), mouse anti-calbindin-D28k (CB, 1:1000; Swant,
Marly, Fribourg, Switzerland), goat anti-PV (1:1000;
Swant), and rabbit anti-calretinin (CR, 1:1000; Swant). All
primary antibodies were diluted in 5 % NGS in 0.1 M PBS
and cells were incubated for 2 hours at room temperature
followed by washing in 0.1 M PBS.
Secondary fluorophore-conjugated antibodies (1:500
for all) included Alexa-568 goat anti-mouse, Alexa-488
goat anti-mouse, Alexa-568 goat anti-rabbit, Alexa-488
goat anti-rabbit, Alexa-488 goat anti-guinea pig, Alexa-
555 goat anti-chicken, Alexa-647 goat anti-chicken, and
Alexa-568 donkey anti-goat (Invitrogen). Antibodies
were diluted in 5 % NGS in 0.1 M PBS and cells were in-
cubated for 1 hour followed by washing in 0.1 M PBS.
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In all experiments, DNA counterstain 4′,6-diamidino-
2-phenylindole (DAPI; Molecular Probes, Thermo Fisher
Scientific) was applied before coverslipping with Pro-
Long gold anti-fade reagent (Invitrogen). Control experi-
ments included either omission of each primary
antibody from the protocol or the inclusion of the ap-
propriate IgG control to verify the specificity of each
antibody. Resulting sections were examined with a
Nikon confocal laser scanning microscope (Nikon In-
struments Inc., Melville, NY, USA).
Stereology for cultured cells was assessed by manually
quantifying immunolabeled cells at a magnification of ×
60 using the confocal microscope. Cells in two wells
were analyzed for each immunocytochemical stain. Cell
counts were performed at six randomly selected sites
within each culture well. The total number of cells im-
munoreactive for Tuj1, GABA, Nestin, GFAP, SOX2,
and Ki67 was determined and expressed as a percentage
of the total number of HuNu-positive cells.
Preparation of cells for transplantation
SVZ-hNSCs were prepared for transplantation by treat-
ing neurospheres with 0.01 % DNase/DMEM for 20 mi-
nutes at 37 °C followed by rinsing in 0.01 % DNase/
DMEM and centrifugation at 190 × g for 5 minutes, re-
suspension in 0.01 % DNase/DMEM, and gentle tritur-
ation into a single-cell suspension.
SVZ-hNSCs were predifferentiated in preparation for
transplantation by culturing neurospheres in the presence
of BDNF and neural supplements as described earlier.
After 7 days, differentiated SVZ-hNSCs were collected
and centrifuged at 190 × g for 5 minutes, and a single-cell
suspension was made prior to transplantation.
Undifferentiated SVZ-hNSCs or predifferentiated cell
suspensions comprised a final cell concentration of
400,000 cells/μl and ≥90 % viability for transplantation.
Experimental design
Surgical transplantation
Seven days after ET-1-induced stroke, rats were re-
anesthetized as already described. A total of 800,000
cells in 2 μl were delivered to each graft site via a
Hamilton syringe attached to a glass capillary (open
diameter 50–70 μm). The glass capillary was left in place
for a further 5 minutes after each dose before retrieval.
A total of eight graft sites relative to the bregma were
chosen across the striatum and cortex as follows: Site 1,
1.4 mm anterior, –4.9 mm lateral, –3 and –5 mm ven-
tral; Site 2, 1.4 mm anterior, –2.8 mm lateral, –3.6 and –
5.6 mm ventral; Site 3, 0.2 mm anterior, –3.8 mm lateral,
–4.8 and –5.8 mm ventral; and Site 4, –2.16 mm anter-
ior, –6 mm lateral, –3.3 and –4.3 mm ventral. All rats
were immunosuppressed by daily intraperitoneal injec-
tions of cyclosporine (10 mg/kg intraperitoneally daily;
Sandimmune, Novartis Pharmaceuticals, East Hanover,
NJ, USA) commencing 2 days prior to cell transplantation.
Functional assessments
Neurological assessments were conducted on all rats
prior to any surgical procedures (pre surgery), immedi-
ately prior to ET-1-induced stroke (0 hours post stroke),
24 and 48 hours post stroke, 7 days after stroke (day 0
post transplant), and again 7 and 28 days post trans-
plant. Forelimb asymmetry was analyzed using a cylinder
test and the percentage of forelimb placements made on
the wall of the plexiglass cylinder during rearing was de-
termined using the methods of Schallert et al. [34]. Ani-
mals were also tested for neurological abnormalities and
assigned deficit scores based on abnormal posture and
hemiplegia as described previously [32, 33, 35, 36]. All
scores from each rat post stroke were compared with
prestroke scores, and thus each rat acted as its own
control.
Tissue processing and analysis
Rats were re-anesthetized 28 days post transplant and
transcardially perfused with 300 ml ice-cold PBS (0.1 M,
pH 7.4) followed by 300 ml cold 4 % PFA (in PBS, 0.1
M, pH 7.4) for 15 minutes. Forebrains were removed
and post-fixed overnight in 4 % PFA in 0.1 M PBS at 4 °C
followed by cryoprotection overnight in 0.1 M PBS with
30 % sucrose at 4 °C. Brains were then frozen and coronal
sections (40 μm) prepared using a cryostat and processed
as free-floating tissue sections.
In vivo immunohistochemistry
Immunofluorescence staining was performed on tissue
sections to analyze and quantify graft survival, matur-
ation, and differentiation as described previously [26].
Briefly, free-floating tissue sections were blocked using
standard immunohistochemical techniques with 5 %
NGS (or 1 % BSA [Sigma] for all staining with goat anti-
PV antibody) in 0.3 % Triton X-100 in 0.1 M PBS before
SVZ-hNSCs were identified using primary antibodies in-
cluding mouse anti-HuNu (1:1000; Millipore), rabbit
anti-Tuj1 (1:1000; Covance Inc.), rabbit anti-GABA
(1:1000; Sigma), rabbit anti-Nestin (1:1000; Millipore),
rabbit anti-GFAP (1:1000; DAKO), rabbit anti-NeuN
(1:1000; Millipore), rabbit anti-Ki67 (1:500; Thermo
Fisher Scientific), rabbit anti-SOX2 (1:400; Millipore),
rabbit anti-GAD (1:1000; Millipore), rabbit anti-SYN
(1:200; Sigma), chicken anti-Tuj1 (1:200; Millipore),
mouse anti-CB (1:1000; Swant), goat anti-PV (1:1000;
Swant), rabbit anti-CR (1:1000; Swant), rabbit anti-
cleaved caspase-3 (Casp3, 1:500; Cell Signaling Technol-
ogy, Boston, MA, USA), and rabbit anti-von Willebrand
Factor (vWF, 1:200; Millipore).
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Secondary fluorophore-conjugated antibodies (1:500
for all) included Alexa-568 goat anti-mouse, Alexa-488
goat anti-mouse, Alexa-350 goat anti-mouse, Alexa-488
goat anti-rabbit, Alexa-647 goat anti-rabbit, Alexa-555
goat anti-chicken, Alexa-647 goat anti-chicken, and
Alexa-568 donkey anti-goat (Invitrogen). Antibodies
were diluted in blocking solution.
For all experiments, DNA counterstain DAPI (Molecular
Probes, Thermo Fisher Scientific ) was applied before cov-
erslipping with ProLong gold anti-fade reagent (Invitrogen).
Control studies included either omission of each primary
antibody from the protocol or the inclusion of the appro-
priate IgG control to verify the specificity of each antibody.
Staining for terminal transferase-mediated dUTP nick end-
labeling (TUNEL) was performed using a TUNEL staining
kit (Promega DeadEnd Colorimetric TUNEL system; Pro-
mega, Madison, WI, USA) according to the manufac-
turer’s instructions. Stained sections were examined with
a Nikon confocal laser scanning microscope (Nikon In-
struments, Melville, NY, USA). Orthogonal projections




Eight predetermined coronal planes throughout the brain
from 3.2 to –6.8 mm relative to the bregma [33] were col-
lected for NeuN staining. Triplicate sections from each level
were visualized with an Olympus (Albertslund, Denmark)
microscope and stroke-damaged regions were identified as
areas with distinct absence of NeuN stain, which was ana-
lyzed using ImageJ software (NIH, Bethesda, MD, USA)
[37–39]. The infarct volume was determined by inte-
grating the cross-sectional area of damage at each
stereotaxic level and the distance between the levels
[40], with edema corrected for as described previously
[33, 41].
Stereological analysis
The optical fractionator stereological method was
used to obtain unbiased estimates of the total number
of HuNu-positive nuclei within undifferentiated and
predifferentiated cell graft sites (n = 7/group) using Stereo
Investigator software (MBF Bioscience, Williston, VT,
USA) [20, 25, 42]. Briefly, every third section was analyzed
using a fluorescence microscope (BH-2; Olympus, Tokyo,
Japan) equipped with a QIClick scientific camera
(QImaging, Surrey, BC, Canada) at a magnification of ×
60, where a three-dimensional optical dissector counting
probe (x, y, z dimensions of 30 μm× 30 μm× 10 μm re-
spectively) was applied to a systematic random sample of
sites within the cell graft [25]. Only HuNu-positive cells
with clearly visible fluorescence were quantified.
Cell phenotyping
The number of HuNu-positive cells that expressed Tuj1,
GABA, Nestin, GFAP, and Ki67 was manually counted
for phenotypic analysis of cells in vivo within transplant
sites. Cells were considered colocalized if labeling of
markers was seen throughout the extent of the HuNu-
positive nucleus or if a cytoskeletal/cytoplasmic marker
surrounded the HuNu-positive nuclear marker. Quanti-
tative analysis was performed in three tissue sections
280 μm apart per graft site (four graft sites/rat) using
z-scan confocal microscopy at × 40 magnification for
animals that received undifferentiated SVZ-hNSCs or
predifferentiated cells (n = 7/group) as described previ-
ously [43–47]. Briefly, estimates of the total number of
cells colocalizing with markers of interest were ob-




where E is the estimate of the total number of stained
cells in each case, ∑N is the sum of n values in the three
sections analyzed, and k indicates that every kth section
was considered (k = 8). N was corrected according to
Abercrombie’s formula:
N ¼ nt= t þ Dð Þ
where n is the number of cells counted in each section, t is
the section thickness, and D is the mean diameter of the
cells [48]. Colocalized cell counts were expressed as the per-
centage of the total number of HuNu-positive cells.
Because of the positioning of hNSC grafts, very few
sections collected contained the exact same anatomical
region within the SVZ for accurate comparisons of host
neurogenesis across all rats. For this reason, only a quali-
tative assessment of the influence of exogenous trans-
plants on host neurogenesis was made.
Statistical analysis
Data obtained in the cylinder test were analyzed by two-
way repeated-measures analysis of variance (ANOVA)
followed by the Bonferroni post-hoc test to compare dif-
ferences between treatment groups over time. Data ob-
tained for infarct area and volume assessments were
analyzed by two-way ANOVA followed by the Bonfer-
roni post-hoc test. Neurological deficit scores were
analyzed by Kruskal–Wallis nonparametric ANOVA
followed by Dunn’s post test. We performed a post-hoc
power calculation to arrive at 73 % where P <0.01, in
which deficits were considered improved by a score
of 1 with a standard deviation of 0.87. All cell counts
were analyzed by two-way ANOVA followed by the
Bonferroni post-hoc test to compare treatment groups
and graft sites. Data were analyzed with GraphPad
Prism, version 6 (GraphPad Software Inc., San Diego,
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CA, USA) and presented as mean ± standard error of
the mean (SEM). Statistical significance was defined
as P <0.05.
Results
In vitro characterization of cells
Confocal analysis of immunolabeled undifferentiated
SVZ-hNSCs in vitro revealed formation of neurospheres
that were colocalized with HuNu and the undifferenti-
ated cell marker SOX2 (98.9 ± 0.7 %) (Fig. 1a). These
cells also colocalized with proliferation marker Ki67
(59.5 ± 3.1 %) and NSC marker Nestin (95.1 ± 0.7 %)
(Fig. 1b), but did not express early neuronal marker
Tuj1, inhibitory neurotransmitter GABA, GABA-
producing enzyme GAD, or immature neuronal marker
DCX (Fig. 1c–f ). In contrast, predifferentiated SVZ-
hNSCs labeled with HuNu were positive for Tuj1
(92.3 ± 1.4 %) (Fig. 1g), GABA (90.1 ± 2.7 %) (Fig. 1h),
GAD (Fig. 1i), and DCX (Fig. 1j). Very few prediffer-
entiated cells expressed Ki67 (9.6 ± 2.5 %) (Fig. 1k) or
Nestin (28.5 ± 2.6 %, Fig. 1l) and SOX2 (12.1 ± 1.7 %,
Fig. 1m). No expression of GFAP, SYN, or the intra-
cellular calcium binding proteins (CBPs) CB, CR, or
PV was detected in vitro.
Transplant studies
Treatment groups
A total of 21 rats were included in this study. Seven rats
were excluded prior to stem cell transplant based on low
stroke severity scores and minimal functional deficits de-
tected at 7 days [32, 33]. Only rats with a stroke rating
of 4 and a clear functional deficit of ≥3 were randomly
assigned to three experimental groups (n = 7/group):
Group 1 received media without any cells (vehicle
control); Group 2 received undifferentiated SVZ-
hNSC transplants; and Group 3 received predifferen-
tiated cells.
Functional outcomes
Cylinder test No significant bias in forelimb use upon
rearing was detected using the cylinder test prior to
stroke induction in any treatment group. After stroke,
all rats exhibited asymmetrical limb use indicative of
stroke damage with preferential ipsilateral (unimpaired)
forelimb use during rearing (Fig. 2a). While transplantation
of either undifferentiated SVZ-hNSCs and predifferentiated
SVZ-hNSCs appeared to decrease forelimb asymmetry
after treatment, this effect was only statistically significant
in rats receiving predifferentiated hNSCs at 7 and 28 days
post transplant in comparison with vehicle control rats re-
ceiving media alone (Fig. 2a) (P <0.05, two-way ANOVA).
Neurological deficit score No neurological deficits
were observed prior to ET-1-induced stroke. However,
significant deficits were observed in all treatment groups
between 24 hours and 7 days after stroke (day 0 post
transplant) (P <0.001, nonparametric ANOVA) (Fig. 2b).
By 28 days, rats receiving vehicle control or undifferenti-
ated hNSCs showed significant recovery in their deficits
when compared with pretransplant scores (P <0.01).
Rats that received predifferentiated hNSCs demonstrated
earlier recovery with significant improvements observed
7 days post transplant (P <0.001) when compared with
pretransplant scores, with no significant deficits detected
28 days post transplant when compared with prestroke
scores (P >0.05).
Infarct assessment
Absence of NeuN immunoreactivity revealed stroke-
induced damage to the parietal, insular, and frontal cor-
tex, as well as the striatum as reported previously [33].
Both infarct area (Fig. 2c, d) and infarct volume (Fig. 2e)
within the cortex and striatum were consistent across
treatment groups with no significant differences detected
between groups (P >0.05, two-way ANOVA).
Characterization of cells within grafts
Cell counts HuNu immunostaining revealed large num-
bers of SVZ-hNSCs within each graft site situated both
within and outside the damaged regions 28 days post
transplant. Although rats receiving undifferentiated hNSCs
displayed evidence of cells within each transplant site,
many HuNu-positive NSCs were also detected beyond the
transplant regions and were also visible within the infarct
border zone. Rats that received predifferentiated SVZ-
hNSCs showed dense clustering of cells within each site.
Stereological cell counting revealed significantly fewer un-
differentiated SVZ-hNSCs within the cortex and striatum
(64,712 ± 16,866 cells and 260,278 ± 14,112 cells respect-
ively) compared with predifferentiated HuNu-positive cells
in cortical and striatal graft regions (444,852 ± 22,181 and
508,098 ± 10,031 cells respectively) (P <0.0001; Fig. 3a).
A greater number of predifferentiated (P <0.05) and
undifferentiated (P <0.0001) SVZ-hNSCs remained
within striatal grafts compared with cortical graft
sites (Fig. 3a). However the overall percentage of
transplanted predifferentiated cells remaining within
cortical and striatal graft sites (27.8 ± 1.3 % and 31.8
± 0.5 % respectively) was significantly higher than
that of undifferentiated SVZ-hNSCs within the cor-
tex and striatum (4.0 ± 1.0 % and 16.3 ± 0.9 % re-
spectively) (P <0.0001; Fig. 3b).
Survival of transplanted cells within graft sites was
confirmed by immunohistochemical analysis for apop-
totic marker Casp3 and TUNEL staining. Negligible
Casp3 immunostaining (Fig. 3c–e) and TUNEL
(Fig. 3f, g) staining was observed within cells 28 days
post transplant. The low level of TUNEL staining
Abeysinghe et al. Stem Cell Research & Therapy  (2015) 6:186 Page 6 of 19
within the graft was similar to that observed within
the contralateral hemisphere (Fig. 3h). Many trans-
planted undifferentiated SVZ-hNSCs were associated
within the glial scar and were GFAP-positive (Fig. 3i,
j), whilst transplanted predifferentiated cells were
clearly associated with blood vessels within the in-
farcted regions (Fig. 3k).
Cell phenotypes Confocal image analysis 28 days post
transplant revealed undifferentiated SVZ-hNSCs mainly
Fig. 1 Undifferentiated hNSCs and predifferentiated cell phenotypes in vitro. Immunofluorescent confocal images of undifferentiated SVZ-hNSCs in
culture expressed HuNu (red) and SOX2 (green) (a), and Ki67 (red) and Nestin (green) (b), with colocalization giving a yellow appearance. Undifferentiated
SVZ-hNSCs immunopositive for HuNu (red) (c–f) in culture were not observed to express Tuj1 (green) (c), GABA (green) (d), GAD (green) e, or DCX (green) f.
Predifferentiated cells cultured for 7 days demonstrated immunoreactivity for HuNu (red) g–m and colabeled with Tuj1 (green) (g), GABA (green) (h), GAD
(green) (i), and DCX (green) (j). Predifferentiated cells HuNu (red) cultured for 7 days demonstrated little immunoreactivity for Ki67 (green) (k), Nestin (green)
(l), or SOX2 (green) (m). Scale bar: (a–f) 100 μm, (g–m) 50 μm. DCX doublecortin, GABA gamma-aminobutyric acid, GAD glutamate decarboxylase 65&67,
HuNu human specific nuclear antigen, Tuj1 β-III tubulin
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expressed markers for GFAP and Nestin (Fig. 4a, b),
with many cells also positive for Ki67 (Fig. 4c). Some un-
differentiated SVZ-hNSCs were also found to express
GABA and Tuj1 (Fig. 4d, e). In contrast, predifferen-
tiated cells mainly expressed Tuj1 and GABA (Fig. 4f, g)
with little colabeling with Nestin and Ki67 (Fig. 4h, i)
and a distinct lack of GFAP expression (Fig. 4j).
Immunofluorescent NeuN staining was used to con-
firm positioning of graft sites within the infarcted region
for stereological analysis across all groups receiving
SVZ-hNSC transplants (Fig. 5a–h). Cell counts within
each site revealed that there were significantly less cells
that expressed Tuj1 (6.6 ± 1.3 %; P <0.0001) and GABA
(5.4 ± 1.4 %; P <0.0001) for undifferentiated SVZ-hNSC
grafts compared with predifferentiated cell grafts (Tuj1:
89.6 ± 1.9 %; GABA: 94.3 ± 1.6 %) across all transplant
sites (Fig. 5i–l, ANOVA). Conversely, there was a
significantly greater proportion of undifferentiated SVZ-
hNSCs that expressed markers for GFAP (93.0 ± 1.9 %;
P <0.0001), Nestin (88.1 ± 2.8 %; P <0.0001), and Ki67
(11.9 ± 1.6 %; P <0.05) compared with transplanted pre-
differentiated cells (GFAP: 4.7 ± 1.3 %; Nestin: 11.6 ± 3.3
%; Ki67: 4.6 ± 1.1 %) (Fig. 5i–l).
Further confocal analysis revealed that predifferentiated
SVZ-hNSC grafts expressed GAD65/67 (Fig. 6a), as well as
the intracellular CBPs CB (Fig. 6b), CR (Fig. 6c), and PV
(Fig. 6d). In addition, predifferentiated SVZ-hNSCs were
observed to express SYN that was mostly localized to the
cell body of cells transplanted into the core infarct region
(Fig. 6e), but was also additionally observed along the
Fig. 2 Functional outcome following transplantation. Effects of transplantation on contralateral limb use when rearing (a) in the cylinder test after
ET-1-induced stroke. Data are mean ± standard error of the mean (SEM) expressed as a percentage of contralateral (impaired) forelimb use. Each
rat acted as its own control; results following stroke were compared with 0-hour prestroke scores. ϕP <0.05, ϕϕP <0.01, ϕϕϕϕP <0.0001 relative
to 0-hour poststroke baseline scores for vehicle-treated rats (n = 7); **P <0.01, ***P <0.001, ****P <0.0001 compared with 0-hour poststroke
baseline scores for undifferentiated treated rats (n = 7); #P <0.05, ##P <0.01 relative to 0-hour poststroke baseline scores for predifferentiated
treated rats (n = 7); δP <0.05, δδP <0.01 vehicle-treated rats compared with predifferentiated treated rats; φφP <0.01 vehicle-treated rats compared
with undifferentiated treated rats; †P <0.05 predifferentiated treated rats compared with undifferentiated treated rats (two-way ANOVA followed
by Bonferroni post test). Combined neurological deficit scores (b). Data presented as box plots include hinges extending from the 25th to 75th
percentiles, the median line within the box and whiskers extending to the minimum and maximum values of the dataset (n = 7/group). *P <0.05,
***P <0.001, ****P <0.0001 relative to 0-hour poststroke baseline scores (n = 7/group); #P <0.05, ##P <0.01, ###P <0.001, ####P <0.0001 relative to
pretransplant scores (Kruskal–Wallis ANOVA followed by Dunn’s test). Effect of transplanting vehicle, undifferentiated hNSCs, or predifferentiated
cells on infarct area (c), (d) and total infarct volume (e) within the cortex and striatum. Data presented as mean ± SEM of infarct area measured at
eight predetermined coronal planes through the brain (two-way ANOVA followed by Bonferroni post test)
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Fig. 3 Transplanted cells survive within the stroke affected brain. Total number (a) and percentage (b) of HuNu-positive cells remaining within cortical
and striatal grafts from undifferentiated (n = 7) and predifferentiated (n = 7) treatment groups. Data presented as mean ± SEM. ****P <0.0001 relative to
undifferentiated treated animals in the same region; ####P <0.0001 relative to undifferentiated grafts within the cortex; ϕP <0.05 relative
to predifferentiated grafts within the striatum (two-way ANOVA followed by Bonferroni post test). Transplanted cells immunopositive for
HuNu (red) (c, f) did not express apoptotic markers including Casp3 (green) (d), merged image (e), or TUNEL (g), with the level of TUNEL staining similar
to the contralateral mirror image (h). Transplanted HuNu-positive (red) predifferentiated cells were associated with vWF-stained blood vessels (green)
within infarcted brain regions (i). Many HuNu-positive undifferentiated hNSCs (red) were found within border regions consisting of GFAP-positive
astrocytes (green) (j). Magnified immunofluorescent image (k) corresponds to box highlighted in (j) illustrating incorporation of undifferentiated hNSCs
into the glial scar bordering the infarct. Scale bar: (c–e) 20 μm, (f–h) 100 μm, (i, k) 200 μm, (j) 100 μm. C contralateral hemisphere, Casp3 cleaved
caspase-3, GFAP glial fibrillary acidic protein, HuNu human specific nuclear antigen, I ipsilateral hemisphere, TUNEL terminal transferase-mediated dUTP
nick end-labeling, vWF von Willebrand factor
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cytoskeleton of cells that were transplanted into sites out-
side of the infarct within the peri-infarct territory (Fig. 6f).
Predifferentiated SVZ-hNSC grafts located within the peri-
infarct territory appeared to extend long neurites revealed
by HuNu and Tuj1 immunostaining (Fig. 6g). Grafts lo-
cated within the core infarct were surrounded by the glial
scar consisting of densely packed GFAP-positive astrocytes,
with limited dispersion of SVZ-hNSCs in closest proximity
to the scar (Fig. 7a–c). Parallel negative control experiments
omitting primary antibodies depict a low level of autofluo-
rescence within the core infarct (Fig. d–f).
Effect of cell transplantation on the neurogenic niche
To investigate the effects of SVZ-hNSC transplant on
endogenous recovery mechanisms we examined changes
within the neurogenic niche in response to stem cell
transplant. Confocal analysis revealed an apparent
increase in the number of Ki67-positive proliferating
cells within the ipsilateral SVZ of rats that received pre-
differentiated SVZ-hNSCs in comparison with rats that
received undifferentiated SVZ-hNSCs or vehicle controls
(Fig. 8a–f ). In particular, immunofluorescent labeling of
cells within the SVZ revealed an apparent increase in
the number of newly generated DCX-positive neurons in
rats with predifferentiated SVZ-hNSC transplants in
comparison with the contralateral SVZ, and rats with
undifferentiated hNSC transplants or vehicle controls
(Fig. 8b, d, f ). Further analysis of immunolabeled cells
within the SVZ revealed an apparent increase in the
number of GFAP-positive radial glial cells with long pro-
cesses directed towards the infarct that did not colocal-
ize with Nestin in animals that received predifferentiated
SVZ-hNSC transplants compared with the contralateral
SVZ, and compared with the other treatment groups
Fig. 4 Undifferentiated hNSCs and predifferentiated cell phenotypes in vivo. Confocal immunofluorescent photomicrographs of undifferentiated
hNSCs at 28 days post transplant within cortical border regions with orthogonal reconstructions. Undifferentiated hNSCs maintained expression of
HuNu (red) and colabeled mainly with GFAP (a), Nestin (b), and Ki67 (c), with little expression of GABA (d) and Tuj1 (e) (green). Immunofluorescent
confocal images of predifferentiated cells 28 days post transplant within the stroke-damaged cortex maintained expression of HuNu (red) colabeled
with Tuj1 (f), GABA (g), Nestin (h), and Ki67 (i) (green), with lack of colocalization with GFAP (green) (j). Orthogonal reconstructions from confocal z-series
are presented as viewed in x–z (top) and y–z (right) planes. HuNu immunoreactivity of undifferentiated hNSCs was observed completely surrounded
by GFAP and Nestin, while HuNu immunoreactivity of predifferentiated cells was observed completely surrounded by Tuj1 and GABA. Scale bar: (a–e)
50 μm, orthogonal images 5 μm; (f–j) 20 μm, orthogonal images 5 μm. GABA gamma-aminobutyric acid, GFAP glial fibrillary acidic protein, HuNu
human specific nuclear antigen, Tuj1 β-III tubulin
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(Fig. 8g–l). Furthermore, cells identified within the
neurogenic niche of the SVZ were not immunopositive
for HuNu, a marker of hNSCs.
Discussion
The use of undifferentiated stem cells for treatment of
neurological diseases including stroke have undergone
intense investigation in preclinical models [49–51].
Undifferentiated stem cells are thought to provide
trophic factor support to injured or “depressed” neural
circuitry and respond to host microenvironmental cues
by migrating and differentiating into various cell types to
influence functional recovery. An alternative approach
to cell-based therapies, however, includes predifferen-
tiating hNSCs prior to transplant to improve func-
tional outcomes in animal models of Huntington’s
Fig. 5 Phenotypic profile of transplanted undifferentiated hNSCs versus predifferentiated cells. Coronal sections immunostained with NeuN
(green) highlight undamaged brain regions with lack of staining within stroke affected areas (white dotted line) at cortical graft sites +1.4 mm
and –2.16 mm relative to the bregma (a, c) and striatal graft sites +1.4 mm and +0.2 mm relative to the bregma (e, g); white boxes depict graft
location. Representative images of graft sites stained with HuNu (red) and NeuN (green) (b, d, f, h) from regions highlighted by white boxes
(a, c, e, g). Numbers of HuNu-positive cells coexpressing Tuj1, GABA, Nestin, GFAP, and Ki67 from undifferentiated hNSC-treated (n = 7) and
predifferentiated cell-treated (n = 7) animals from cortical graft sites; +1.4 mm (i) and –2.16 mm (j) relative to the bregma; and striatal graft sites +1.4
mm (k) and +0.2 mm (l) relative to the bregma. Numbers of cells are presented as a percentage of the total number of HuNu-positive cells counted.
Data are mean ± SEM. ***P <0.001, ****P <0.0001 compared with undifferentiated hNSC counts (two-way ANOVA with Bonferroni post test). Scale bar:
(a, c, e, g) 2000 μm, (b, d, f, h) 200 μm. GABA gamma-aminobutyric acid, GFAP glial fibrillary acidic protein, HuNu human specific nuclear antigen, NeuN
neuron specific nuclear antigen, Tuj1 β-III tubulin
Abeysinghe et al. Stem Cell Research & Therapy  (2015) 6:186 Page 11 of 19
Fig. 6 (See legend on next page.)
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disease, Parkinson’s disease, and neuropathic pain
models [25, 26, 28].
Here we report the first evidence in a model of stroke
for accelerated improvement in motor function follow-
ing transplantation of predifferentiated human GABAer-
gic hNSCs compared with undifferentiated hNSCs. We
demonstrate that GABAergic neuronal transplants sur-
vive within the stroke-affected rat brain, mature, and ex-
tend processes with evidence of synaptogenesis and
calcium signaling events associated with neurotransmis-
sion. Moreover, rats receiving predifferentiated cells
showed evidence of increased endogenous neurogenesis,
with immature neurons seen extending from the SVZ
towards the damaged striatum. In contrast, undifferenti-
ated SVZ-hNSC transplants predominantly differentiated
into astrocytes and appeared to contribute to scar for-
mation within the peri-infarct border zone. Our results
suggest that differentiation of hNSCs into a neuronal
phenotype prior to transplant may be a favorable strat-
egy for in vivo cell restoration and improved motor
function after stroke.
In vitro cell phenotyping
In vitro differentiation of SVZ-hNSCs prior to trans-
plantation at day 7 revealed a highly enriched popula-
tion of GABAergic neurons that expressed Tuj1, GABA,
and GAD [29]. The expression of both GAD isoforms
(65 and 67) confirmed functional differentiation of these
cells with an ability for neurons to produce and release
GABA [52, 53] and excluded the possibility of GABA
immunoreactivity resulting from in vitro uptake [28].
The decreased expression of markers Nestin, Ki67, and
SOX2 with in vitro differentiation was consistent with
phenotypic GABAergic conversion. Predifferentiated
cell cultures comprised few Ki67-positive cells indicat-
ing the majority of cells had undergone differentiation. In
contrast, examination of undifferentiated hNSCs revealed a
larger population of Nestin, Ki67, and SOX2 immunoposi-
tive cells. Furthermore, previous in vitro analysis of predif-
ferentiated hNSCs using our GABAergic predifferentiation
protocol has already shown that differentiation does not re-
sult in the expression of markers for oligodendrocytes, D2
dopamine receptors, or postsynaptic glutamate receptors.
Fig. 7 Predifferentiated cells grafted to the core infarct in vivo. Predifferentiated cell graft (HuNu, red) (a) located within the infarcted core region was
surrounded by GFAP-positive astrocytes on one side (green) (b) that form the glial scar border (arrow) and merge (c), with dispersion of HuNu-positive
cells observed in the core furthest away from the scar (arrowheads). Negative control; omission of primary antibodies (d–f). Scale bar: (a–f) 100 μm.
GFAP glial fibrillary acidic protein, HuNu human specific nuclear antigen
(See figure on previous page.)
Fig. 6 Further maturation of predifferentiated cells 28 days post transplant. Confocal photomicrographs of predifferentiated cells 28 days post
transplant within the stroke-damaged brain expressed HuNu (red) double labeled with either GAD65/67 (green) (a), calbindin-D28k (CB; green)
(b), or calretinin (CR, green) (c). Predifferentiated cells expressing HuNu (blue) triple-labeled with parvalbumin (PV, green) and GABA (red) (d), or
triple-labeled with Tuj1 (red) and presynaptic vesicle protein synaptophysin (SYN, green) within the cortical core (e) and border (f) regions. Some
predifferentiated cells expressing HuNu (red) grafted to border regions appeared to extend long neurites expressing Tuj1 (green) (g). Orthogonal
reconstructions from confocal z-series are presented as viewed in x–z (top) and y–z (right) planes. Scale bar: (a, b) 10 μm, orthogonal image 5 μm;
(c, d) 40 μm, orthogonal image 5 μm; (e, f) 10 μm, orthogonal image 5 μm; (g) 20 μm, orthogonal image 5 μm. GABA gamma-aminobutyric acid,
GAD glutamate decarboxylase 65&67, HuNu human specific nuclear antigen, Tuj1 β-III tubulin
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It does, however, result in downregulation of precursor cell
associated markers and leads to the majority of hNSCs ex-
pressing GABAergic neuronal phenotypic markers [28].
Taken together, differentiation in vitro results in downregu-
lation of stem cell markers and an upregulation of neur-
onal markers where the majority of predifferentiated
cells displayed a GABAergic neuronal phenotype [29].
Effect of cells on functional recovery
Treatment with differentiated GABAergic hNSCs accel-
erates functional recovery when compared with rats
treated with undifferentiated hNSCs. In particular,
neurological deficit scores were improved at earlier
times after stroke in comparison with undifferentiated
hNSC-treated rats. Recovery observed in GABAergic
cell-treated rats 28 days post transplant was consistent
with prestroke neurological scores. Unlike other treat-
ments, GABAergic cell treatment resulted in statistically
improved forelimb asymmetry, comparable with pre-
stroke asymmetry. These results show that differenti-
ation into a GABAergic cell lineage prior to transplant
has beneficial effects on recovery for both the cortical
and subcortical motor systems.
Transplant survival and migration
Only rats with the same stroke severity scores were in-
cluded in these experiments, which resulted in little
variation detected between infarct volumes across treat-
ments. As such we were able to assess cell responses to
the host microenvironment without having to take into
account variations in brain injury between groups [32].
Despite the aforementioned findings, a comparison of
cell survival 28 days post transplant between treatment
groups was difficult due the apparent migration of un-
differentiated cells away from the graft site. In our
study, only 16 % of undifferentiated hNSCs were de-
tected within striatal grafts and only 4 % within cortical
grafts 28 days post transplant. Undifferentiated hNSCs
favor less hostile environments and have previously
been reported to migrate towards border regions [54,
55], which could account for the low cell numbers
detected in the original grafts. For this reason, the peri-
infarct territory is currently the target area for trans-
plantation because it is thought to be less hostile and
may provide a more supportive extracellular matrix for
cell grafts to anchor [22, 37, 56]. In contrast, we now
show for the first time that a greater percentage of cells
Fig. 8 Effect of treatment on endogenous neurogenesis and radial glial populations within the SVZ. Immunofluorescent images of proliferating
cells (Ki67; red) and migrating immature neuroblasts (DCX; green) within the contralateral and ipsilateral SVZ of vehicle-treated (a, b), undifferentiated
hNSC-treated (c, d), and predifferentiated cell-treated (e, f) animals. Nestin (green; arrowheads) and GFAP (red) immunopositive cells (coexpression giving
a yellow appearance; arrows) within the contralateral and ipsilateral SVZ of vehicle-treated (g, h), undifferentiated treated (i, j), and
predifferentiated treated (k, l) animals. All images were taken at the same anatomical location from animals with similar infarct volumes.
Scale bar: (a–f) 500 μm, (g–l) 50 μm. CC corpus callosum, DCX doublecortin, GFAP glial fibrillary acidic protein, LV lateral ventricle, Prediff
predifferentiated treated, Stm Striatum, Undiff undifferentiated hNSC treated
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can be retained in the target region if stem cells are pre-
differentiated. Approximately 30 % of GABAergic cell
transplants were still detected in cortical and striatal
graft sites even within the severely damaged brain 28
days post transplant. These cells were not in a state of
decay since they did not stain positive for apoptotic
markers Casp3 or TUNEL stain.
Previous reports suggest that between 0.5 and 15 % of
exogenously grafted cells survive in the core infarct and
only 20–30 % survive in locations distant to the infarct
[18–22]. We now show that cell retention following
transplant can be improved through predifferentiation,
albeit some cell loss is probably necessary since pruning
and refinement of cell numbers to facilitate development
of efficient networks is an important process during
development [57, 58]. Our findings may support the
delivery of fewer cells while still achieving therapeutic
outcomes.
The question remains: how do GABAergic cells sur-
vive within the severely damaged brain? The answer may
relate to trophic factor support provided from blood ves-
sels detected within and surrounding grafts [59–61].
Angiogenesis occurs as early as 3 days after ET-1 stroke
[62] and is thought to provide a platform for brain re-
pair. Cells grafted to sites of revascularization after
stroke might be expected to do better [62–64]. Current
clinical trials favor delaying cell-based treatments until
behavioral deficits reach a steady plateau and the micro-
environment is less aggressive [11, 65]. Unfortunately,
delaying treatment also allows time for newly formed
vasculature to regress [66]. Our results suggest that cell-
based therapies may benefit from a developed micro-
vascular bed for optimizing survival and influence of ex-
ogenous grafts on functional recovery. Timing cell-based
therapy within weeks after stroke, when standard thera-
peutic procedures have been exhausted and relative
stabilization of the infarct has occurred, may be a more
suitable option for intervention.
Posttransplant histology
Immunohistochemical analysis revealed predominant
differentiation of hNSCs into GFAP-positive astrocytes
28 days post transplant in all brain regions targeted. As-
trocytes are becoming recognized as a restorative thera-
peutic target for brain injury, including stroke, because
their phenotype can mediate aspects of brain integrity,
neuronal cell death, and repair [67]. Astrocyte activation
and reactive astrogliosis can result in both beneficial and
deleterious responses, and is dependent on the intensity
and hostility of the stroke-damaged environment [32, 67,
68]. In the ET-1 stroke model, reactive astrogliosis and
glial scarring is established by 14 days [62] and is a
major obstacle to brain repair and functional recovery
[69, 70]. For this reason we chose not to transplant cells
into an established glial scar, but rather targeted trans-
plant prior to scar formation. Nonetheless, hNSCs that
were not predifferentiated prior to transplant were found
to be localized within the glial scar by 28 days and in-
tensely stained with GFAP, indicating posttransplant dif-
ferentiation. Undifferentiated hNSCs also displayed a
significantly greater proliferative capacity as indicated by
Ki67 immunoreactivity compared with predifferentiated
cells, confirming their capacity for self-renewal and
expansion after transplant. Interestingly, a small sub-
population of undifferentiated hNSCs spontaneously
differentiated into Tuj1 and GABA-expressing neu-
rons by 28 days, demonstrating their ability to enter a
neuronal lineage despite a greater propensity towards
glial cell formation [55, 56].
In contrast to the above, immunohistochemical ana-
lysis of predifferentiated GABAergic cell transplants re-
vealed robust expression of Tuj1, GABA, and GAD
within the cell bodies, confirming their GABAergic
neuronal phenotype 28 days post transplant, even in the
severely damaged brain. Predifferentiated cells displayed
low levels of proliferative potential, without aberrant
transdifferentiation. Furthermore, they did not revert
back to an undifferentiated state, suggesting these cells
could be a safe source for transplantation. As such, pre-
differentiating cells into neurons prior to transplant may
provide a better treatment option by reducing the risk of
contributing to glial scar and tumor formation [71]. Fu-
ture studies investigating the effects of undifferentiated
hNSC or predifferentiated cell transplants on non-
neuronal host cells would be of great interest to deter-
mine the extent of their influence and thus provide a
well-rounded perspective of their potential.
Neuronal repopulation and trophic support for functional
recovery
How GABAergic transplants improve the recovering
brain is yet to be fully determined. GABAergic neu-
rons are the principal inhibitory cells of the mammalian
central nervous system and occur throughout the brain,
and GABA regulates the proliferation of neural progeni-
tor cells [72, 73], migration [74], and other aspects of
neurogenesis including differentiation [75, 76], neurite
formation [77], and synaptogenesis [78]. Possible mech-
anisms of recovery following stroke injury therefore in-
clude neuronal repopulation to bridge the gap between
damaged circuits, rescue or reactivation of dormant but
surviving circuitry, and trophic influences on endogen-
ous neurogenesis and neuronal reconstruction.
In our study, GABAergic cells transplanted into the
striatum resulted in >30 % new neurons expressing im-
munohistochemical markers that are typically expressed
by striatal GABAergic medium-sized spiny projection
neurons and aspiny interneurons, being positive for
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GABA, GAD, Tuj1, and CBPs that are essential compo-
nents for restoring neurotransmission [79–83]. Whilst
grafts to the core infarct were clearly isolated by the
glial scar barrier by 28 days, grafts within the border
zone appeared to be better positioned to influence host
circuitry and promote recovery. Future studies using an-
terograde and retrograde labeling would be required to
substantiate connectivity of graft cells to host neural
systems [84].
GABAergic cell transplants also upregulated markers
that were absent at the time of transplant, indicating fur-
ther maturation in vivo to potentially aid recovery. In our
study, only predifferentiated cells expressed SYN, a pre-
synaptic vesicle protein, suggesting increased synaptic
vesicle formation with potential roles in neurotransmis-
sion and plasticity [85–87]. The localization of SYN to the
cellular cytoskeleton of grafts within the peri-infarct terri-
tory could indicate a more advanced state of maturation
compared with grafts within the core infarct. Furthermore,
only predifferentiated cells were observed to express the
intracellular CBPs CB, CR, and PV, potentially indicating
calcium signaling events associated with neurotransmis-
sion, transmitter release, and plasticity [88, 89]. Overall,
paracrine delivery of GABA, upregulated SYN, and CBP
expression may restore neurotransmission and promote
plasticity to improve behavioral outcomes.
Another possible outcome of GABAergic transplant
is the awakening of depressed pathways known to lie
dormant following stroke [90–92], either through restor-
ation of neurotransmission or graft-induced enhancement
of neurogenesis to stimulate pathways and influence re-
pair. Trophic and chemoattractive functions exerted by in-
terneurons during development through the release of
depolarizing GABA may be recapitulated by GABAergic
transplants to promote proliferation/migration of en-
dogenous progenitor cells, provide positional cues to mi-
grating cells including immature neurons, and influence
synapse maturation [52, 93, 94]. This is concordant with
the human GABAergic transplants in our study potentially
being immature and therefore excitatory through release
of depolarizing GABA as the switch to an inhibitory
phenotype that only occurs late in the first postnatal year
in humans [95]. Furthermore, within the ipsilateral SVZ,
only predifferentiated cell-treated animals displayed
GFAP-positive radial glial cells with long processes known
to function in guiding immature neurons during neuro-
genesis [96]. Although the endogenous neurogenic re-
sponse purportedly increases 7–14 days post stroke and
returns to normal beyond this time [97], the apparent in-
crease in activity within the neurogenic niche in our study
35 days post stroke suggests a trophic influence from
transplanted GABAergic cells. In addition, the low neuro-
genic response observed in vehicle-treated animals 35
days post stroke supports previous reports demonstrating
basal neurogenesis levels beyond 2 weeks post stroke in
rats [97]. Trophic factors secreted from migrating en-
dogenous progenitor cells and immature neurons, or
GABAergic transplants themselves, could therefore act to
stimulate rewiring or awakening of host circuits, enabling
remaining healthy tissue to restore function of lost con-
nections [92, 98, 99].
Conclusion
Findings from this study demonstrate predifferentiating
SVZ-hNSCs prior to transplantation as a novel strategy to
accelerate functional recovery after cerebral ischemia. In
contrast, undifferentiated hNSC transplants have the poten-
tial to delay or hinder functional improvements through
contributions to further scar formation. Neuronal repopula-
tion through GABAergic neuronal transplants may achieve
greater viability in a clinical setting by targeting a smaller is-
chemic region, as seen in lacunar strokes [100, 101]. How-
ever, GABAergic transplants also show promise for targeting
severe stroke through production of GABA, synaptogenesis,
and calcium signaling events associated with neurotransmis-
sion, to bridge the gap between damaged pathways, enhance
plasticity, or rescue depressed circuitry to re-establish func-
tion. Alternatively, known trophic effects of depolarizing
GABA during development may be recapitulated in our
study to enhance endogenous neurogenesis, reactivate cir-
cuitry, and promote plasticity for functional recovery in se-
vere strokes with widespread damage. The principles behind
differentiation of hNSCs into a desired neuronal cell type
may be a favorable alternative for treating stroke.
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